HER2 Positive Breast Cancer Clinical Trial
Official title:
Feasibility Study of an Adapted Physical Activity (APA) for Breast Cancer Patients Treated by Neoadjuvant Chemotherapy and Targeted Therapy Against HER2
The purpose of this study is to assess the feasibility of a home-based adapted physical activity during neoadjuvant chemotherapy for HER2+ breast cancer.
After the assessment of their physical fitness, a home-based adapted physical activity program composed by aerobic and muscle strengthening exercises will be delivered to each patient. The aim of the intervention is to reach international recommendation in a progressive way during neoadjuvant chemotherapy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01904903 -
Cardiac Safety Study in Patients With HER2 + Breast Cancer
|
Phase 2 | |
| Completed |
NCT02476539 -
Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT01840306 -
Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer
|
||
| Completed |
NCT03735966 -
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.
|
Phase 2 | |
| Recruiting |
NCT01785420 -
Pre Operative Trastuzumab in Operable Breast Cancer
|
Phase 3 | |
| Recruiting |
NCT05132582 -
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
|
Phase 3 | |
| Terminated |
NCT00817362 -
Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT03947242 -
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.
|
N/A | |
| Terminated |
NCT02213744 -
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT02362958 -
A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT02614794 -
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
|
Phase 2 | |
| Completed |
NCT03013504 -
A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients
|
Phase 3 | |
| Completed |
NCT02682693 -
Denosumab as an add-on Neoadjuvant Treatment (GeparX)
|
Phase 2 | |
| Completed |
NCT02125344 -
A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
|
Phase 3 | |
| Active, not recruiting |
NCT04539938 -
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT05252988 -
Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib
|
Phase 2 | |
| Completed |
NCT02705859 -
Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study)
|
Phase 1 | |
| Active, not recruiting |
NCT02993198 -
A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging
|
Phase 2 |